Hepatitis B Topics HBV Disease Progression Decompensation & ESLD
EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
Tenofovir Improves Outcomes of HBV Acute-on-Chronic Liver Failure
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 10 May 2011 09:06
- Written by Liz Highleyman
Treatment with tenofovir (Viread) lowers HBV viral load, reduces liver injury, and decreases the risk of death in patients with acute-on-chronic liver failure due to hepatitis B reactivation. 
Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.
EASL 2010: Measurable Neurocognitive Impairment Persists after Episodes of Hepatic Encephalopathy in People with Liver Cirrhosis
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 11 May 2010 12:56
- Written by Liz Highleyman
Changes in working memory, psychomotor speed, and other neurocognitive measures persist in patients with hepatic encephalopathy due to decompensated liver cirrhosis, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. A related study presented at the Digestive Disease Week conference (DDW 2010) last week in New Orleans found that more than half of people with compensated cirrhosis (mostly due to hepatitis C) showed signs of neurocognitive impairment, indicating that mild hepatic encephalopathy is common even among individuals without severe liver disease.
Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by James Learned
In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.
Web Design and Development by